- Prophylaxis of kidney transplant rejection:
- >35kg: IV 20mg within 2 hours prior to transplant surgery then IV 20mg 4 days after transplant
- <35kg: IV 10mg within 2 hours prior to transplant surgery then IV 10mg 4 days after transplant
- Withhold 2nd dose if complications such as severe hypersensitivity or graft loss occur after first dose
- Used in regimen containing cyclosporine and corticosteroids
Injection: 20mg
- For central or intravenous administration only
- Infuse over 20-30 min
Monoclonal antibody; Immunosuppressant
It binds to activated T-lymphocyte IL-2 receptor alpha chains thereby antagonizing IL-2
- Constipation
- Nausea & Vomiting
- Abdominal pain
- Diarrhea
- Dyspepsia
- Pain
- Peripheral edema
- Fever
- Viral infection
- Hypokalemia
- Hyperkalemia
- Hyperglycemia
- Hypercholesterolemia
- Hypophosphatemia
- Hyperuricemia
- UTI
- Dyspnea
- URI
- Acne
- Hypertension
- Headache
- Tremor
- Insomnia
Anemia
- Hypersensitivity to class/compound
- It should only be prescribed by physicians who have experience with immunosuppression in organ transplant recipients
- Upadacitinib
- Live bacterial vaccines
Drug Status
| Availability | Prescription only |
| Pregnancy | Category B; Can be used |
| Breastfeeding | Unknown; Weigh risk vs benefit |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Simulect | 20mg | Injection | 1’s | Novartis Pharma | Novartis Kenya |